S Di Gregorio1, L Del Rio1, J Rodriguez-Tolra2, E Bonel3, M García3, R Winzenrieth4. 1. Cetir Grup Mèdic, Barcelona, Spain; Red Temática de Investigación cooperativa en Envejecimiento y Fragilidad - RETICEF, Instituto Carlos III, Barcelona, Spain. 2. Department of Urology, Hospital Universitari de Bellvitge - L'Hospitalet, Spain. 3. Cetir Grup Mèdic, Barcelona, Spain. 4. Med-Imaps, R&D Department, Merignac, France. Electronic address: rwinzenrieth@medimapsgroup.com.
Abstract
PURPOSE: The objective of the study was to assess longitudinal effects of different osteoporosis treatments on TBS and aBMD at lumbar spine. METHOD: We analyzed 390 patients (men: 72; women: 318; age>40 years; mean follow-up of 20 months and BMI<37 kg/m(2)). We stratified the cohort by treatments: Naive of treatment (Naive, n=67), Calcium and Vitamin D (CaVitD, n=87), Testosterone (Te, n=36), Alendronate (AL, n=88), Risedronate (Ri, n=39), Denosumab (Dmb, n=43) and Teriparatide (PTH, n=30). The follow-up changes from baseline were normalized at 24 months. RESULTS: After 24 months, Naive group TBS decreased by 3.1% (p<0.05) whereas a non-significant increase was observed for spine aBMD (Δ=+0.5%). Compared to the Naive group, significant improvement (p<0.05) was observed in both TBS and aBMD for Te, AL, Ri, Dmb and PTH groups and in the CaVitD group for TBS. At the end of the follow-up, significant improvement have been observed for aBMD in Te (+4.4%), AL (+4.1%), Ri (+4.8), D (+8.8%) and PTH (+8.8%) groups. Significant improvement was observed only in the AL (+1.4%), Dmb (+2.8%) and PTH (+3.6%) groups for TBS. CONCLUSION: As expected, TBS of Naive subjects decreased with age. As expected a TBS preservation has been observed under AL and Ri. Te and CaVitD effects on TBS were evaluated for the first time: a similar preservation effect has been observed. A significant TBS increase was observed under Denosumab and PTH. TBS could be a useful tool to monitor treatment effects.
PURPOSE: The objective of the study was to assess longitudinal effects of different osteoporosis treatments on TBS and aBMD at lumbar spine. METHOD: We analyzed 390 patients (men: 72; women: 318; age>40 years; mean follow-up of 20 months and BMI<37 kg/m(2)). We stratified the cohort by treatments: Naive of treatment (Naive, n=67), Calcium and Vitamin D (CaVitD, n=87), Testosterone (Te, n=36), Alendronate (AL, n=88), Risedronate (Ri, n=39), Denosumab (Dmb, n=43) and Teriparatide (PTH, n=30). The follow-up changes from baseline were normalized at 24 months. RESULTS: After 24 months, Naive group TBS decreased by 3.1% (p<0.05) whereas a non-significant increase was observed for spine aBMD (Δ=+0.5%). Compared to the Naive group, significant improvement (p<0.05) was observed in both TBS and aBMD for Te, AL, Ri, Dmb and PTH groups and in the CaVitD group for TBS. At the end of the follow-up, significant improvement have been observed for aBMD in Te (+4.4%), AL (+4.1%), Ri (+4.8), D (+8.8%) and PTH (+8.8%) groups. Significant improvement was observed only in the AL (+1.4%), Dmb (+2.8%) and PTH (+3.6%) groups for TBS. CONCLUSION: As expected, TBS of Naive subjects decreased with age. As expected a TBS preservation has been observed under AL and Ri. Te and CaVitD effects on TBS were evaluated for the first time: a similar preservation effect has been observed. A significant TBS increase was observed under Denosumab and PTH. TBS could be a useful tool to monitor treatment effects.
Authors: A R Hong; J H Kim; K H Lee; T Y Kim; S A Im; T Y Kim; H G Moon; W S Han; D Y Noh; S W Kim; C S Shin Journal: Osteoporos Int Date: 2017-01-12 Impact factor: 4.507
Authors: Muthu Rama Krishnan Mookiah; Thomas Baum; Kai Mei; Felix K Kopp; Georg Kaissis; Peter Foehr; Peter B Noel; Jan S Kirschke; Karupppasamy Subburaj Journal: J Bone Miner Metab Date: 2017-04-07 Impact factor: 2.626
Authors: V Nardone; P Tini; S F Carbone; A Grassi; M Biondi; L Sebaste; T Carfagno; E Vanzi; G De Otto; G Battaglia; G Rubino; P Pastina; G Belmonte; L N Mazzoni; F Banci Buonamici; M A Mazzei; L Pirtoli Journal: Osteoporos Int Date: 2017-02-27 Impact factor: 4.507
Authors: J T Schousboe; T N Vo; L Langsetmo; B C Taylor; A M Kats; A V Schwartz; D C Bauer; J A Cauley; K E Ensrud Journal: Osteoporos Int Date: 2017-10-31 Impact factor: 4.507
Authors: M R McClung; K Lippuner; M L Brandi; J R Zanchetta; H G Bone; R Chapurlat; D Hans; A Wang; C Zapalowski; C Libanati Journal: Osteoporos Int Date: 2017-07-26 Impact factor: 4.507